These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32885562)

  • 21. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.
    McMullen S; Buckley B; Hall E; Kendter J; Johnston K
    Value Health; 2017 Jan; 20(1):93-99. PubMed ID: 28212975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor.
    Georgescu MT; Moorehead PC; Liu T; Dumont J; Scott DW; Hough C; Lillicrap D
    Front Immunol; 2020; 11():138. PubMed ID: 32117285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
    Mahlangu JN; Ragni M; Gupta N; Rangarajan S; Klamroth R; Oldenburg J; Nogami K; Young G; Cristiano LM; Dong Y; Allen G; Pierce GF; Robinson B
    Thromb Haemost; 2016 Jul; 116(1):1-8. PubMed ID: 26962852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
    Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
    BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A.
    Ebbert PT; Xavier F; Malec LM; Seaman CD; Ragni MV
    Thromb Res; 2020 Nov; 195():51-54. PubMed ID: 32653601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.
    Dumont JA; Liu T; Low SC; Zhang X; Kamphaus G; Sakorafas P; Fraley C; Drager D; Reidy T; McCue J; Franck HW; Merricks EP; Nichols TC; Bitonti AJ; Pierce GF; Jiang H
    Blood; 2012 Mar; 119(13):3024-30. PubMed ID: 22246033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16
    Lagassé HAD; Ou J; Sauna ZE; Golding B
    Front Immunol; 2024; 15():1341013. PubMed ID: 38655263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
    Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
    Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
    Kragh N; Tytula A; Pochopien M; Aballéa S; Toumi M; Hakimi Z; Nazir J; Bystrická L; Fatoye F
    Eur J Haematol; 2023 Mar; 110(3):262-270. PubMed ID: 36398467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerating Factor VIII: Recent Progress.
    Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
    Front Immunol; 2019; 10():2991. PubMed ID: 31998296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc).
    Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TAL; Walker ID
    Int J Lab Hematol; 2019 Apr; 41(2):176-183. PubMed ID: 30556650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison.
    Hakimi Z; Santagostino E; Postma MJ; Nazir J
    Adv Ther; 2021 Feb; 38(2):1263-1274. PubMed ID: 33377987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
    Mahlangu J; Powell JS; Ragni MV; Chowdary P; Josephson NC; Pabinger I; Hanabusa H; Gupta N; Kulkarni R; Fogarty P; Perry D; Shapiro A; Pasi KJ; Apte S; Nestorov I; Jiang H; Li S; Neelakantan S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Dodd N; Nugent K; Vigliani G; Luk A; Brennan A; Pierce GF;
    Blood; 2014 Jan; 123(3):317-25. PubMed ID: 24227821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study.
    Malec L; Van Damme A; Chan AKC; Spasova M; Jain N; Sensinger C; Dumont J; Lethagen S; Carcao M; Peyvandi F
    Blood; 2023 Apr; 141(16):1982-1989. PubMed ID: 36735911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.
    Shapiro AD; Mahlangu JN; Perry D; Pasi J; Quon DV; Chowdary P; Tsao E; Li S; Innes A; Pierce GF; Allen GA
    Haemophilia; 2017 May; 23(3):392-399. PubMed ID: 28220631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
    Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
    Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.
    Lehtinen AE; Baghaei F; Astermark J; Holme PA
    Haemophilia; 2022 Sep; 28(5):713-719. PubMed ID: 35575446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa.
    Pitance V; Désage S; Lienhart A; Meunier S; Chamouard V
    Haemophilia; 2021 May; 27(3):e368-e375. PubMed ID: 33780111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.
    Mancuso ME; Mannucci PM
    Drug Des Devel Ther; 2014; 8():365-71. PubMed ID: 24729686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.